3.56
-0.09(-2.47%)
Currency In USD
| Previous Close | 3.65 |
| Open | 3.59 |
| Day High | 3.7 |
| Day Low | 3.51 |
| 52-Week High | 4.08 |
| 52-Week Low | 0.8 |
| Volume | 6.48M |
| Average Volume | 5.47M |
| Market Cap | 934.98M |
| PE | -16.95 |
| EPS | -0.21 |
| Moving Average 50 Days | 2.6 |
| Moving Average 200 Days | 2.01 |
| Change | -0.09 |
If you invested $1000 in Akebia Therapeutics, Inc. (AKBA) 10 years ago, it would be worth $440.59 as of June 15, 2025 at a share price of $3.56. Whereas If you bought $1000 worth of Akebia Therapeutics, Inc. (AKBA) shares 5 years ago, it would be worth $293.49 as of June 15, 2025 at a share price of $3.56.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Vadadustat U.S. Patient Data from Global Phase 3 Clinical Program Published in Journal of the American Society of Nephrology
GlobeNewswire Inc.
Jun 04, 2025 12:00 PM GMT
Akebia continues to publish important, clinically relevant data to further physicians’ understanding of Vafseo® (vadadustat)CAMBRIDGE, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company w
Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference 2025
GlobeNewswire Inc.
May 28, 2025 12:00 PM GMT
CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that Akebia Executive Management wi
Akebia Therapeutics Announces Three Poster Presentations at the European Renal Association Congress 2025
GlobeNewswire Inc.
May 27, 2025 12:00 PM GMT
Vadadustat clinical data on display for nephrologists and healthcare providersCAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people i